Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | MLNR | O43193 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9310887 | 0.98 | IDH2 (0.60) | IDH2MAPK1HTR2CMALT1APP | |
| Hydrochloric Acid SCHEMBL7060324 | 0.98 | IDH2 (0.60) | IDH2MAPK1HTR2CMALT1APP | |
| Hydrochloric Acid SCHEMBL422804 | 0.98 | IDH2 (0.60) | IDH2MAPK1HTR2CMALT1APP | |
| SCHEMBL21856299 | 0.91 | IDH2 (0.73) | IDH2MAPK1HTR2CMALT1APP | |
| Hydrochloric Acid SCHEMBL9312323 | 0.90 | IDH2 (0.71) | IDH2MAPK1HTR2CMALT1APP | |
| SCHEMBL1420520 | 0.89 | MALT1 (0.66) | IDH2MALT1APPLMNAEPHX2 | |
| Hydrochloric Acid SCHEMBL1669945 | 0.87 | MALT1 (0.64) | IDH2MALT1APPLMNAEPHX2 | |
| SCHEMBL18466529 | 0.84 | IDH2 (0.45) | IDH2MAPK1HTR2CMALT1APP | |
| SCHEMBL12076535 | 0.84 | EPHX2 (0.63) | IDH2MALT1PIM1LMNAEPHX2 | |
| SCHEMBL27552253 | 0.83 | HTR6 (0.47) | IDH2MAPK1MALT1APPDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104725356-B | Nitrogen heterocyclic derivatives and application thereof in medicine | 广东东阳光药业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| EP-2508526-A1 | Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators | Ares Trading SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508526-A1 | Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators | Ares Trading SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012130915-A1 | SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS | ARES TRADING S.A. (CH) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012130915-A1 | SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS | ARES TRADING S.A. (CH) | 2012-10-04 | — | — | WO | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2441763-A1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | Glaxo Group Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| WO-2008146064-A1 | NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT7 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION | EGIS GYÓGYSZERGYÁR (HU) | 2008-12-04 | — | — | WO | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| EP-1246795-A2 | ANTIBACTERIAL AGENTS | Tularik Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051456-A2 | ANTIBACTERIAL AGENTS | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | IDH2 781/4885MAPK1 2766/4885HTR2C 3378/4885 |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | IDH2 3633/4885MAPK1 1850/4885HTR2C 68/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | IDH2 4066/4885MAPK1 1649/4885HTR2C 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.